Fox Chase Researchers Demonstrate Key Qualities of New Drug Candidate for Pancreatic Tumors
PHILADELPHIA (August 8, 2023) — A new study led by Igor Astsaturov, MD, PhD, Co-Director of the Marvin & Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center, demonstrates two key components necessary for a new drug candidate, LP-184, to effectively treat pancreatic adenocarcinoma. The findings were published today in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.